Medicine
Kimmtrak 100 mcg/0.5 mL injection
Kimmtrak 100 mcg/0.5 mL injection is a prescription medicine containing Tebentafusp for intravenous use, marketed by Immunocore Commercial, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store KIMMTRAK vials in the original carton refrigerated at 2°C to 8°C (36°F…
Key facts
- Active ingredient (INN)
- Tebentafusp
- Brand
- Kimmtrak
- Strength
- 100 mcg/0.5 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 0.5 mL
- Marketing authorisation holder
- Immunocore Commercial
- Manufacturer
- Immunocore Commercial
- Origin register
- US FDA, United States
- Storage
- Store KIMMTRAK vials in the original carton refrigerated at 2°C to 8°C (36°F to 46°F) and protect from light until time of use. Do not freeze. Do not shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XX75 Tebentafusp
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 26 January 2022
- Identifiers
- RxCUI 2590748, 2590754DailyMed set ID 24a49f57-d2fc-4ffe-9eb1-fe0460c6b067NDC 80446-401Application BLA761228
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / .5 mL in 1 vial, glass | 80446-401-01 | Immunocore Commercial | 26 January 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. It is available as injection for intravenous use. MedsAcross supplies Tebentafusp for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TebentafuspFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- KIMMTRAK prescribing information (Immunocore Commercial) · U.S. National Library of Medicine, DailyMed
- Kimmtrak: European public assessment report (EPAR) · European Medicines Agency
Need Kimmtrak 100 mcg/0.5 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.